The Relationship between Plasma Serotonin and Kynurenine Pathway Metabolite Levels and the Treatment Response to Escitalopram and Desvenlafaxine
ConclusionsIn MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment. (Sour...
Source: Brain, Behavior, and Immunity - January 21, 2020 Category: Neurology Source Type: research

A Scoping Review of the Evidence Behind CYP2D6 Inhibitor Classifications.
The objective was to identify if the classification of currently listed FDA moderate and weak inhibitors is supported by publicly available primary literature. We conducted a literature search and reviewed product labels (PLs) for AUC-fold changes caused by inhibitors in humans and identified 89 inhibitor-substrate pairs. Observed AUC-fold change of the substrate was used to create an observed inhibitor classification per FDA-defined AUC-fold change thresholds. We then compared the observed inhibitor classification with the classification listed in the FDA Table of Inhibitors. We found 62% of the inhibitors within the pair...
Source: Clinical Pharmacology and Therapeutics - January 7, 2020 Category: Drugs & Pharmacology Authors: Cicali EJ, Smith DM, Duong BQ, Kovar LG, Cavallari LH, Johnson JA Tags: Clin Pharmacol Ther Source Type: research

Electrochemical treatment of real hospital wastewaters and monitoring of pharmaceutical residues by using surrogate models
Publication date: October 2019Source: Journal of Environmental Chemical Engineering, Volume 7, Issue 5Author(s): Yassine Ouarda, Florence Bouchard, Antonin Azaïs, Marc-Antoine Vaudreuil, Patrick Drogui, Rajeshwhar Dayal Tyagi, Sébastien Sauvé, Gerardo Buelna, Rino DubéAbstractThe electrochemical oxidation of drug residues in hospital wastewater has been studied. Treatment performances were evaluated by measuring the residual concentrations of twelve pharmaceutical compounds from different categories (caffeine, cihydrocarbamazepine, desvenlafaxine, sulfamethoxazole, venlafaxine, 2-hydroxy ibuprofen...
Source: Journal of Environmental Chemical Engineering - August 17, 2019 Category: Chemistry Source Type: research

The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study
Publication date: Available online 24 June 2019Source: The Lancet PsychiatryAuthor(s): Yun Wang, Joel Bernanke, Bradley S Peterson, Patrick McGrath, Jonathan Stewart, Ying Chen, Seonjoo Lee, Melanie Wall, Vanessa Bastidas, Susie Hong, Bret R Rutherford, David J Hellerstein, Jonathan PosnerSummaryBackgroundAntidepressant medications offer an effective treatment for depression, yet nearly 50% of patients either do not respond or have side-effects rendering them unable to continue the course of treatment. Mechanistic studies might help advance the pharmacology of depression by identifying pathways through which treatments exe...
Source: The Lancet Psychiatry - June 26, 2019 Category: Psychiatry Source Type: research

IJERPH, Vol. 16, Pages 2255: Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis
Conclusions. This scientometric analysis represents comprehensive evidence on the popularity and change in prospects of biological treatments for MDD from 1988 to 2017. The popularity of SSRI peaked between 1998 and 2002, when their efficacy, tolerability and safety profile allowed them to replace the TCAs and MAOIs. While the newer neurostimulation therapies are gaining momentum, the popularity of ECT has sustained. (Source: International Journal of Environmental Research and Public Health)
Source: International Journal of Environmental Research and Public Health - June 26, 2019 Category: Environmental Health Authors: Bach X. Tran Giang H. Ha Giang T. Vu Long H. Nguyen Carl A. Latkin Kalpana Nathan Roger S. McIntyre Cyrus S. Ho Wilson W. Tam Roger C. Ho Tags: Article Source Type: research

Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
CONCLUSION: Early improvement in SDS total score was predictive of functional outcomes for patients treated with desvenlafaxine 50 mg, desvenlafaxine 100 mg, or placebo. PMID: 31060632 [PubMed - as supplied by publisher] (Source: CNS Spectrums)
Source: CNS Spectrums - May 7, 2019 Category: Neurology Authors: Soares CN, Wajsbrot DB, Boucher M Tags: CNS Spectr Source Type: research

Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder
Thickness of the cerebral cortex has been previously investigated for its potential as a biomarker in major depressive disorder (MDD). This is the first study to examine the longitudinal effects of a serotonin-norepinephrine reuptake inhibitor, desvenlafaxine succinate (DVS), on whole-brain cortical thickness (CT) in patients treated for MDD. We also aimed to replicate a previous finding of an association between improvement in clinical severity and CT in one of five predefined regions-of-interest (ROI). Twenty-five individuals with MDD received treatment with DVS (50 mg/day) for 8 weeks, with 19 completing the stud...
Source: NeuroReport - March 4, 2019 Category: Neurology Tags: CLINICAL NEUROSCIENCE Source Type: research

Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.
Authors: Wu L, Gerdts EA, Alam A PMID: 30664338 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - January 23, 2019 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine.
Authors: Garakani A PMID: 30550646 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - December 15, 2018 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
CONCLUSION: Desvenlafaxine 20 to 50 mg/d was generally safe and well tolerated with no new safety signals identified in children and adolescents with MDD who received up to 6 months of treatment in these studies. Patients maintained the reduction in severity of depressive symptoms observed in all treatment groups at the end of the lead-in study. PMID: 30419989 [PubMed - as supplied by publisher] (Source: CNS Spectrums)
Source: CNS Spectrums - November 13, 2018 Category: Neurology Authors: Atkinson S, Thurman L, Ramaker S, Buckley G, Jones SR, England R, Wajsbrot D Tags: CNS Spectr Source Type: research

Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing
Several companies offer pharmacogenetic testing for psychiatry on the basis of the claim that the outcome of drug selection is better when guided by such testing than when such testing is not used. This column examines the results of the GeneSight Psychotropic Test which groups various antidepressants and antipsychotics into 3 bins: green (“use as directed”), yellow (“use with caution”), and red (“use with increased caution and more frequent monitoring”). The authors examined how frequently the same drugs appeared in these different bins in 19 patients. They found that of the 22 antidepr...
Source: Journal of Psychiatric Practice - November 1, 2018 Category: Psychiatry Tags: COLUMNS Source Type: research

Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
CONCLUSION: Milnacipran is a dual reuptake inhibitor of noradrenaline and serotonin, with greater effect on noradrenaline than serotonin, in contrast to the related drugs venlafaxine, desvenlafaxine and duloxetine. Rapidly absorbed irrespective of food, milnacipran has a half-life of approximately 8 hours, reaches steady state in 2 days and is excreted renally. Milnacipran helps a minority of patients with fibromyalgia by reducing pain and fatigue. It is also an effective antidepressant with efficacy comparable to venlafaxine and duloxetine, and a side effect profile characteristic of SNRIs. The dose range is...
Source: Australasian Psychiatry - September 10, 2018 Category: Psychiatry Authors: Keks NA, Hope J, Keogh S, Copolov DL Tags: Australas Psychiatry Source Type: research

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
Conclusion: In our study, patients on desvenlafaxine were associated with less pocket depth and bleeding on probing. (Source: Journal of Indian Society of Periodontology)
Source: Journal of Indian Society of Periodontology - September 3, 2018 Category: Dentistry Authors: Anu Bhatia Rajinder Kumar Sharma Shikha Tewari Satish Chander Narula Hitesh Khurana Source Type: research

A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder
This study sought to assess feasibility and tolerability of using DESV in depressed patients on MMT. A total of 18 depressed individuals on MMT received DESV (50–100 mg/day) for 8 weeks. Participants were assessed for the following: (a) Safety of DESV using Systematic Assessment for Treatment Emergent Events-GI, ECG [corrected Q-T (QTc) interval measurement] and methadone serum levels; (b) depressive symptoms using Montgomery–Äsberg Depression Rating Scale (MADRS); and (c) other outcomes including anxiety, suicidality, craving, substance use, quality of life, and other depression scales. Registratio...
Source: International Clinical Psychopharmacology - July 31, 2018 Category: Psychiatry Tags: Original Articles Source Type: research

Switch to a manic episode after desvenlafaxine discontinuation in bipolar disorder.
e;ndez MA, García-Álvarez G PMID: 30079929 [PubMed - in process] (Source: Actas Espanolas de Psiquiatria)
Source: Actas Espanolas de Psiquiatria - July 1, 2018 Category: Psychiatry Authors: Muquebil Ali Al Shaban-Rodríguez OW, Álvarez de Morales E, Rodríguez-Turiel C, Fernández-Menéndez MA, García-Álvarez G Tags: Actas Esp Psiquiatr Source Type: research

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research
Journal of Child and Adolescent Psychopharmacology, Ahead of Print. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - April 5, 2018 Category: Pediatrics Authors: Jeffrey R. Strawn Paul E. Croarkin Source Type: research

Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study.
CONCLUSIONS: In patients with anxiety or depressive disorder, the risk of antidepressant-emergent sexual dysfunction at 6 weeks is low when drug doses are initially low with gradual up-titration. Baseline sexual dysfunction was independently associated with impaired sexual outcome. Men may be more likely than women to experience impaired sexual outcome. In patients with baseline sexual dysfunction, prescription of mirtazapine might be preferable to fluoxetine. PMID: 29588433 [PubMed - in process] (Source: East Asian Archives of Psychiatry)
Source: East Asian Archives of Psychiatry - March 29, 2018 Category: Psychiatry Tags: East Asian Arch Psychiatry Source Type: research

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
CONCLUSIONS: The update did not change the major findings of the previous review. Based on low- to very low-quality evidence, the SNRIs duloxetine and milnacipran provided no clinically relevant benefit over placebo in the frequency of pain relief of 50% or greater, but for patient's global impression to be much or very much improved and in the frequency of pain relief of 30% or greater there was a clinically relevant benefit. The SNRIs duloxetine and milnacipran provided no clinically relevant benefit over placebo in improving health-related quality of life and in reducing fatigue. Duloxetine and milnacipran did not signi...
Source: Cochrane Database of Systematic Reviews - February 28, 2018 Category: General Medicine Authors: Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W Tags: Cochrane Database Syst Rev Source Type: research

Drug & ndash;drug interactions involving antidepressants: focus on desvenlafaxine
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - February 19, 2018 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research

Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database
ConclusionSCCS shows promise for signal detection: it may highlight known associations for recent marketed products and has potential for early signal identification. SCCS performance varied by design choice and the nature of both exposure and event pair. Future work is needed to determine how effective the approach is in prospective testing and determining the performance characteristics of the approach. (Source: Drug Safety)
Source: Drug Safety - January 11, 2018 Category: Drugs & Pharmacology Source Type: research

Risk of hair loss with different antidepressants: a comparative retrospective cohort study
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupr...
Source: International Clinical Psychopharmacology - January 1, 2018 Category: Psychiatry Tags: Original Articles Source Type: research

An open ‐label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)‐(–)‐O‐desmethylvenlafaxine and racemic O‐desmethylvenlafaxine
This study compared the serotonin transporter (SERT) occupancy achieved by SEP‐227162 and ODV, at daily doses of 25, 50, 100, and 150 mg using [11C]DASB positron emission tomography (PET). Sixteen healthy male subjects participated in one of four dose groups (N = 4 per group) during which they were administered two doses of the study drug (SEP‐227162 or ODV). For each study drug, total daily doses of 25, 50, 100, and150 mg were studied. Subjects underwent three PET scans with [11C]DASB. A baseline, off‐medication, scan was performed prior to dosing and a [11C]DASB PET scan was performed after 72 hr at e...
Source: Synapse - December 13, 2017 Category: Neurology Authors: W. Gordon Frankle, Brigitte Robertson, Gary Maier, Jennifer Paris, Deanna Asmonga, Maureen May, Michael L. Himes, N. Scott Mason, Chester A. Mathis, Rajesh Narendran Tags: RESEARCH ARTICLE Source Type: research

Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations
Clinical Pharmacology in Drug Development,Volume 7, Issue 4, Page 441-450, May 2018. (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - December 11, 2017 Category: Drugs & Pharmacology Authors: Alice I.Nichols , SamLiao , RichatAbbas Source Type: research

An Open ‐Label Positron Emission Tomography (PET) Study to Evaluate Serotonin Transporter Occupancy Following Escalating Dosing Regimens of (R)‐(‐)‐O‐desmethylvenlafaxine and Racemic O‐Desmethylvenlafaxine
This study compared the serotonin transporter occupancy achieved by SEP‐227162 and ODV, at daily doses of 25mg, 50mg, 100mg and 150mg using [11C]DASB positron emission tomography (PET). Methods: Sixteen healthy male subjects participated in one of four dose groups (N = 4 per group) during which they were administered two doses of the study drug (SEP‐227162 or ODV). For each study drug, total daily doses of 25mg, 50mg, 100mg and150mg were studied. Subjects underwent three PET scans with [11C]DASB. A baseline, off‐medication, scan was performed prior to dosing and a [11C]DASB PET scan was perform after 72 hours at eac...
Source: Synapse - December 8, 2017 Category: Neurology Authors: W. Gordon Frankle, Brigitte Robertson, Gary Maier, Jennifer Paris, Deanna Asmonga, Maureen May, Michael L Himes, N. Scott Mason, Chester A. Mathis, Rajesh Narendran Tags: Research Article Source Type: research

Risk of hair loss with different antidepressants: a comparative retrospective cohort study
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupr...
Source: International Clinical Psychopharmacology - December 1, 2017 Category: Psychiatry Tags: Original Articles Source Type: research

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - November 30, 2017 Category: Pediatrics Authors: Karen L. Weihs William Murphy Richat Abbas Deborah Chiles Richard D. England Sara Ramaker Dalia B. Wajsbrot Source Type: research

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - November 29, 2017 Category: Pediatrics Authors: Sarah Atkinson Shannon Lubaczewski Sara Ramaker Richard D. England Dalia B. Wajsbrot Richat Abbas Robert L. Findling Source Type: research

Takotsubo Cardiomyopathy and Intraoperative Cardiac Arrest: Is Desvenlafaxine a Contributing Factor?
Takotsubo cardiomyopathy (TTC), otherwise known as stress-induced cardiomyopathy (broken heart syndrome) is characterized by rapidly reversible heart failure with transient left ventricular wall motion abnormality without the presence of significant coronary artery disease.1 According to a review, perioperative TTC occurs in 1 of 6,700 surgical procedures.2 (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 16, 2017 Category: Anesthesiology Authors: Usha Gurunathan Tags: Letter to the Editor Source Type: research

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.
Abstract OBJECTIVE: This post-hoc pooled analysis evaluated categorical change in functional impairment in patients with major depressive disorder (MDD) treated with desvenlafaxine versus placebo and examined whether early improvement in functioning predicted functional outcomes at study endpoint. METHODS: Data were pooled from eight randomized, double-blind, placebo-controlled studies of desvenlafaxine for the treatment of MDD, including adults who were randomly assigned to receive desvenlafaxine 50 or 100 mg/d or placebo (N=3,384). Shift tables were generated for categorical changes in functional impairment...
Source: CNS Spectrums - November 15, 2017 Category: Neurology Authors: Soares CN, Zhang M, Boucher M Tags: CNS Spectr Source Type: research

Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome.
CONCLUSION: MB is a useful additional strategy for severe drug induced vasodilatory shock and may be potentially life-saving. Clinicians should be aware that it can interact with other drugs and cause life-threatening Serotonin Syndrome. Lower doses or shorter durations may be wise in patients at risk of this interaction. PMID: 29134498 [PubMed - as supplied by publisher] (Source: Journal of Medical Toxicology)
Source: Journal of Medical Toxicology - November 13, 2017 Category: Toxicology Authors: Chan BS, Becker T, Chiew AL, Abdalla AM, Robertson TA, Liu X, Roberts MS, Buckley NA Tags: J Med Toxicol Source Type: research

Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations
Abstract Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single‐ and multiple‐dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added to a population PK model previously developed using sparse PK samples from patients with major depressive disorder, including 140 Korean patients, combined with rich PK data from healthy volunteers. The structural PK model was an open 1‐compartment linear disposition model with parallel first‐order and 0‐order inputs. The effects of Korean status on apparent oral cleara...
Source: Clinical Pharmacology in Drug Development - November 1, 2017 Category: Drugs & Pharmacology Authors: Alice I. Nichols, Sam Liao, Richat Abbas Tags: Original Manuscript Source Type: research

Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors.
This study examined the incidence and pattern of antidepressant-related JS and its predictors. METHODS: 209 patients diagnosed with any anxiety or depressive disorder and started on mirtazapine, sertraline, desvenlafaxine, escitalopram or fluoxetine were assessed at baseline, after 2 weeks, and after 6 weeks with psychopathology rating scales and for predefined categories of JS. RESULTS: The incidence of JS during the 6-week study was 27.7%, but only 6.7% in first 2 weeks. JS rates were similar in anxiety and depressive disorders. Mirtazapine was associated with the lowest rate of 14.3%, and other antidepressants w...
Source: Asian Journal of Psychiatry - October 26, 2017 Category: Psychiatry Tags: Asian J Psychiatr Source Type: research

The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine
We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50–100 mg/day for 8 weeks. Multiple regression analyses modeled improvement in work functioning measures (Lam Employment Absence and Productivity Scale, Health and Work Performance Questionnaire, Sheehan Disability Scale) with measures of fatigue (Patient-Reported Outcomes Measurement Informat...
Source: International Clinical Psychopharmacology - September 28, 2017 Category: Psychiatry Tags: Original Articles Source Type: research

Prediction of human efficacious antidepressant doses using the mouse forced swim test
Publication date: Available online 6 September 2017 Source:Pharmacology Biochemistry and Behavior Author(s): Eunice Yuen, Steven Swanson, Jeffrey M. Witkin The forced swim test (FST) is a commonly used preclinical animal behavioural model for prediction of antidepressant activity in humans. While the FST may qualitatively predict efficacy, less is known about the quantitative translation of FST data to human efficacious doses. Assessing quantitative translation allows better predictions of human efficacious doses and a higher chance of success in the drug development process. Dose-response and time-course FST experiments ...
Source: Pharmacology Biochemistry and Behavior - September 7, 2017 Category: Biochemistry Source Type: research

Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use
AbstractOral desvenlafaxine extended-release [Deller® (Brazil); Pristiq® (USA)] is a second-generation, selective serotonin-noradrenalin reuptake inhibitor that is indicated for the treatment of major depressive disorder (MDD) in adults. In this population, desvenlafaxine is an effective and generally well tolerated treatment, significantly improving symptoms of depression and functional outcomes compared with placebo in 8-week double-blind trials, with these benefits maintained during longer-term therapy. In addition, desvenlafaxine is an effective and generally well tolerated treatment in postmenopausal women wit...
Source: Drugs and Therapy Perspectives - September 2, 2017 Category: Drugs & Pharmacology Source Type: research

A standardization of the Novelty-Suppressed Feeding Test protocol in rats
Publication date: 29 September 2017 Source:Neuroscience Letters, Volume 658 Author(s): Arantxa Blasco-Serra, Eva M. González-Soler, Ana Cervera-Ferri, Vicent Teruel-Martí, Alfonso A. Valverde-Navarro Tests based on hyponeophagia phenomena are the most widely used to check the efficacy and efficiency of new-generation chronic antidepressant treatments. Even so, these tests lack strict consensus about their methodology, which reduces their validity, reproducibility and makes translatability difficult. Therefore, after an extensive literature review on this subject, we propose a methodological protocol for the ...
Source: Neuroscience Letters - September 1, 2017 Category: Neuroscience Source Type: research

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
Conclusions: These findings suggest that clinicians may be able to use depression rating scale scores early in treatment as a guide to inform treatment optimization. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - August 31, 2017 Category: Psychiatry Tags: Original Contributions Source Type: research

The prospective, 24-week assessment of cost-efficacy of and compliance to antidepressant medications in a rural setting (PACECAR) study.
CONCLUSIONS: Reasons for noncompliance vary by drug class and need to be considered when prescribing antidepressant drugs. Escitalopram, sertraline, and desvenlafaxine perhaps have the most favorable 24-week cost-efficacy profile; tricyclics are poorly tolerated. Rural subjects need to be educated that treatment must be continued even after improvement is established. PMID: 28827861 [PubMed - in process] (Source: Indian Journal of Psychiatry)
Source: Indian Journal of Psychiatry - August 24, 2017 Category: Psychiatry Tags: Indian J Psychiatry Source Type: research

Desvenlafaxine Appears to Improve Low Energy in Major Depression
Desvenlafaxine appears to improve energy and diminish lassitude in patients with major depressive disorder (MDD), with a significant association between improvements in energy/fatigue and overall functional outcomes, according to areport in theJournal of Psychopharmacology.“Fatigue and lack of energy may have a significant impact on MDD patient functioning, including cognitive functioning at school and at work,” wrote Raymond W. Lamb, M.D., of the University of British Columbia and colleagues. “[I]t is critical for clinicians to treat energy symptoms in patients with depression and to address residual ene...
Source: Psychiatr News - July 27, 2017 Category: Psychiatry Tags: desvenlafaxine Journal of Psychopharmacology lassitude low energy major depressive disorder Pfizer Raymond Lamb Source Type: research

Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder
This study evaluates the involvement of nine common antidepressants in the NLRP3-inflammasome complex (fluoxetine, paroxetine, mianserin, mirtazapine, venlafaxine, desvenlafaxine, amitriptyline, imipramine and agomelatine), both in in vitro THP-1 cells stimulated by ATP, and in a stress-induced depressive animal or MDD patients. Antidepressant treatment induced inflammasome inhibition was observed by decreased serum levels of IL-1β and IL-18 and decrease of NLRP3 and IL-1β (p17) protein expression. This was also observed under stress-induced depressive behaviour and inflammasome activation in C57Bl/6 mice in vivo...
Source: Pharmacological Research - May 3, 2017 Category: Drugs & Pharmacology Source Type: research

[Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor].
CONCLUSIONS: Although evidence of desvenlafaxine in neuropathic pain is scarce, it presents some interesting pharmacokinetic properties, as it is not substrate or have activity on P-glycoprotein, and have a metabolism which practically does not depend on cytochrome P450 system, which limits the risk of pharmacokinetic interactions and potential problems associated tolerability when administered with drugs that are CYP2D6 moderate or potent inhibitors or other substrates of this isoenzyme. These characteristics make desvenlafaxine a different antidepressant especially useful in some subgroups of patients with chronic pain (...
Source: Revista de Neurologia - February 25, 2017 Category: Neurology Authors: Alcantara-Montero A Tags: Rev Neurol Source Type: research

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline
Purpose: This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. Methods: Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term, placebo-controlled, major depressive disorder studies (N = 4279). Effects of age (18–40 years,>40 to (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - February 23, 2017 Category: Psychiatry Tags: Original Contributions Source Type: research

Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study
Conclusions:Patients with comorbid depression and insomnia who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those with adult onsets of these comorbid disorders. Further research is needed to identify therapies that enhance the depression and insomnia treatment responses of those with childhood onsets of these two conditions.Citation:Edinger JD, Manber R, Buysse DJ, Krystal AD, Thase ME, Gehrman P, Fairholme CP, Luther J, Wisniewski S. Are patients with childhood onset of insomnia and depression more difficult to treat than are those with adult onse...
Source: Journal of Clinical Sleep Medicine : JCSM - February 15, 2017 Category: Sleep Medicine Source Type: research

Multi-residue determination of micropollutants in Phragmites australis from constructed wetlands using microwave assisted extraction and ultra-high-performance liquid chromatography tandem mass spectrometry.
Abstract In constructed wetlands micropollutants can be removed from water by phytoremediation. However, micropollutant uptake and metabolism by plants here is poorly understood due to the lack of good analytical approaches. Reported herein is the first methodology developed and validated for the multi-residue determination of 81 micropollutants (pharmaceuticals, personal care products and illicit drugs) in the emergent macrophyte Phragmites australis. The method involved extraction by microwave accelerated extraction (MAE), clean-up using off-line solid phase extraction and analysis by ultra-high-performance liqu...
Source: Analytica Chimica Acta - February 6, 2017 Category: Chemistry Authors: Petrie B, Smith BD, Youdan J, Barden R, Kasprzyk-Hordern B Tags: Anal Chim Acta Source Type: research

Tramadol vs. Everything: 744 Drug Interactions and Counting
​​BY THOMAS BARROWS, MDA 43-year-old woman presented to our emergency department with complaints of anxiety, intermittent “cramping” in her left hand, and jerking movements of her body that had been going on for five days. She had depression following the death of her son 14 months earlier, for which she was started on Effexor 37.5 mg once daily two weeks earlier.​One week before this visit, the patient had back pain and headache, for which she was evaluated at a local emergency department. She had lumbar x-rays showing mild degenerative changes in her spine and a normal head CT scan. The emergency p...
Source: The Case Files - January 17, 2017 Category: Emergency Medicine Tags: Blog Posts Source Type: research

Development and evaluation ofDesvenlafaxine loaded PLGA-Chitosan nanoparticles for brain delivery
Publication date: Available online 23 December 2016 Source:Saudi Pharmaceutical Journal Author(s): Gui-Feng Tong, Nan Qin, Li-Wei Sun Depression is a debilitating psychiatric condition that remains the second most common cause of disability worldwide. Currently, depression affects more than 4 percent of the world’s population. Most of the drugs intended for clinical management of depression augment the availability of neurotransmitters at the synapse by inhibiting their neuronal reuptake. However, the therapeutic efficacy of antidepressants is often compromised as they are unable to reach brain by the conventional r...
Source: Saudi Pharmaceutical Journal - December 24, 2016 Category: Drugs & Pharmacology Source Type: research

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
Conclusion: Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing. (Source: Pharmacogenetics and Genomics)
Source: Pharmacogenetics and Genomics - December 8, 2016 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets
Conclusion: A controllable release pattern of DSV was achieved using Methocel, Maltodextrin and SCMC. The obtained results could be used as a platform to control the release of cationic water soluble drugs that suffer from side effects associated with their initial burst after oral administration. (Source: Saudi Pharmaceutical Journal)
Source: Saudi Pharmaceutical Journal - November 2, 2016 Category: Drugs & Pharmacology Source Type: research

Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects
. (Source: Clinical Toxicology)
Source: Clinical Toxicology - September 13, 2016 Category: Toxicology Authors: J. M. Cooper J. A. Brown R. Cairns G. K. Isbister Source Type: research